Please assess the completion status of the following clinical trial:

Trial Title: Ciliation and Mucus Rheology Parameters Determined Via Air-liquid-interface Cell Cultures in Non-smoking, Smoking, COPD and Asthmatic Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion criteria for non smoking controls:~* The subject has given free and informed consent and signed the consent form~* The subject is affiliated with or beneficiary of a medical insurance program~* The subject has never smoked~* No obstructive breathing disorder (forced expiratory volume at one second (FEV1) \>70% of predicted value; the ratio of FEV1 to forced vital capacity (FEV1/FVC) is \> 0.7)~* No known respiratory disease~Inclusion criteria for smokers without COPD:~* The subject has given free and informed consent and signed the consent form~* The subject is affiliated with or beneficiary of a medical insurance program~* Smoker or former smoker (\>= 30 pack years)~* No obstructive breathing disorder (forced expiratory volume at one second (FEV1) \>70% of predicted value; the ratio of FEV1 to forced vital capacity (FEV1/FVC) is \> 0.7)~Inclusion criteria for smokers with COPD:~* The subject has given free and informed consent and signed the consent form~* The subject is affiliated with or beneficiary of a medical insurance program~* Smoker or former smoker (\>= 30 pack years)~* Subject presenting with COPD: FEV1/FVC \< 0.7 (based on spirometry values in the medical file and performed in the 3 months prior to inclusion)~* The subject requires bronchial fibroscopy (decision made by pneumologist)~* COPD of grade 2 or 3 according to GOLD criteria (Global Initiative for Chronic Obstructive Lung Disease)~Inclusion criteria for subjects with severe asthma:~* The subject has given free and informed consent and signed the consent form~* The subject is affiliated with or beneficiary of a medical insurance program~* Non-smoker or former smoker (\<10 pack years)~* Subject presenting with severe asthma: FEV1/FVC \>= 0.7 and FEV1 \< 80%~* The subjects requires bronchial fibroscopy (decision made by pneumologist)~Exclusion criteria:~* The subject has an extensive neoplastic disease~* The subject has another active lung disease (tuberculosis, pulmonary interstitium disease, active or recent pulmonary infection)~* The subject has had a recent psychiatric disorder (within one year prior to inclusion and documented by a specialist consultation)~* Emergency situations (object extractions...)~* Subject consuming illicit drugs or alcohol~* The subject is in an exclusion period determined by a previous study~* The subject is under judicial protection, or is an adult under any kind of guardianship~* It is impossible to correctly inform the patient~* The subject cannot fluently read French

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Non-smoking controls (Type: EXPERIMENTAL): Subjects in this group have never smoked and have no known lung disorders.~Intervention: Bronchial Biopsy + ALI culture (Air Liquid Interface)
- Smokers without COPD (Type: EXPERIMENTAL): Subjects in this group are smokers or former smokers who do not have signs of obstructive disease (no chronic obstructive pulmonary disease (COPD))~Intervention: Bronchial Biopsy + ALI culture
- Smokers with COPD (Type: EXPERIMENTAL): Subjects in this group are smokers or former smokers who have COPD~Intervention: Bronchial Biopsy + ALI culture
- Severe asthma (Type: EXPERIMENTAL): Subjects in this group are non-smokers or former (light) smokers who have severe asthma.~Intervention: Bronchial Biopsy + ALI culture

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility